Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 3
Author: Motilal Oswal

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK | BSE: 532296 | ISIN: INE935A01035 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

2116.3000 64.40 (3.14%)

NSE Sep 09, 2025 15:31 PM

65.92% Gain from 52W Low

Volume: 1.3M

Glenmark Pharmaceuticals Ltd.

16 Aug 2021

2116.30

3.14%

In-line 1QFY22; DF drives overall earnings growth

Neutral: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

In-line 1QFY22; DF drives overall earnings growth Motilal Oswal values your support in the Asiamoney Brokers Poll 2021 for India Research, Sales, Corporate Access and...

Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.